Drug Delivery
(ALKS) Alkermes Retains Neutral Recommendation
We maintain our Neutral rating on Alkermes, Inc. (ALKS) with a price target of $11.50.
Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies...
(HSP) Hospira Earnings Comes in Well Ahead of Expectations
Hospira (HSP) reported strong fourth quarter and full year 2009 results. Earnings per share (EPS) came in at 87 cents, well above the Zacks Consensus Estimate of 70 cents and the year-ago earnings of 78 cents.
Revenues...
(ALKS) Alkermes Reports Lower Third Quarter Loss
Alkermes Inc. (ALKS) reported a third quarter fiscal 2010 net loss of 3 cents per share (excluding items but including stock based compensation) compared with a loss of 9 cents in the year-ago period (excluding...
(PETS) PetMed Express Beats Consensus Estimates
PetMed Express, Inc. (PETS), America’s largest Pet Pharmacy, recently reported third-quarter fiscal 2010 results. The quarterly earnings of 25 cents a share were above the Zacks Consensus Estimate by 2...
(HSP) Hospira Carries Out Restructuring Plan
Hospira (HSP) is carrying out its restructuring plans in an attempt to reduce its operating expenses. The company is reducing its workforce by 10% (1400-1500 employees), which would result in savings of $110...
(NKTR) Nektar Therapeutics Announces Preliminary Data
Recently, Nektar Therapeutics (NKTR) announced preliminary results from the first stage of phase II study of its experimental ovarian cancer drug, NKTR-102. It has been observed that the drug, tested in women...
(NKTR) Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year
by Marc Lichtenfeld, Healthcare Expert
Wednesday, January 6, 2010: Issue...
(HSP) Hospira Aquires Pharmaceuticals Business
Hospira (HSP) has been making certain strategic moves in the recent past; the latest deal will establish its presence in one of the most sought after emerging market ? India. Hospira decided to acquire India-based...
(ALKS) Good News for Alkermes’ Drug Pipeline
Recently, Alkermes Inc. (ALKS) announced that its drug Vivitrol, which is indicated for the treatment of alcohol dependence, also helped opioid addicts stay away from drugs. Data from the six-month late-stage...
(ALKS) Alkermes Moves to Loss but Beats Consensus Estimates
Alkermes, Inc. (ALKS) reported a second quarter fiscal 2010 net loss of 5 cents per share, compared with a profit of 2 cents in the year-ago period. The Zacks Consensus Estimate was a loss of 10 cents.
Revenues...
(NKTR) The F.I.R.S.T. System: Searching For the “Holy Grail” of Investing
by Marc Lichtenfeld, Healthcare Expert
Wednesday, October 28, 2009: Issue...
(HSP) Hospira Surges Ahead
Hospira (HSP) reported third quarter earnings of 90 cents per share, well above both the Zacks Consensus Estimate of 68 cents and 63 cents per share in the year-ago period. Revenues increased 8.9% to $1 billion,...
(PETS) PetMed Express In-Line with Consensus Estimates
PetMed Express, Inc. (PETS), the America ’s largest Pet Pharmacy, recently reported second-quarter 2010 results. The quarterly earnings of 28 cents a share came in line with the Zacks Consensus Estimate but rose 12% year-on-year from 25 cents posted in the...
(ALKS) Good News for Alkermes’ Drug Pipeline
Recently, Alkermes Inc. (ALKS) announced that its pipeline candidate, ALKS33, for addiction and nervous system disorders, gave positive results in two early stage clinical trials. Results from the two studies, ALK33-003 and ALK33-004, demonstrated that the...
(BVF) Biovail Corporation Continues with Pimavanserin
Biovail Corporation (BVF) recently provided an update on its development plans for pimavanserin for Parkinson’s disease psychosis (PDP). The company is developing the candidate in collaboration with Acadia Pharmaceuticals, Inc. (ACAD) and...
(ELN) SEC Subpoena for Elan Regarding Tysabri Use Disclosure
Elan Corporation (ELN) recently received a subpoena from the US Securities and Exchange Commission (SEC) regarding the company’s disclosure of two brain disorder cases (in July 2008), often fatal, tied to the use of its drug Tysabri for the treatment of...
(NKTR) Nektar Therapeutics Presents Favorable Phase II Trial Data
Recently, Nektar Therapeutics (NKTR) presented data from its phase II trial of oral NKTR-118, meant for the treatment of opioid-induced constipation. The data was presented at the American Academy of Pain Management’s 20th Annual Clinical Meeting in...
(HSP) Hospira Ups 2009 Earnings Guidance
Lake Forest, Illinois-based specialty pharmaceutical products maker Hospira (HSP) recently raised its 2009 outlook. The company now sees earnings in the range of $2.80 to $2.85 per share up from its earlier guidance of $2.70 to $2.75.
Annual revenue...
(ALKS) Alkermes Notified Johnson & Johnson Intends to Stop Development of Risperidone
On Wednesday, Alkermes, Inc. (ALKS) disclosed that it has received notification from Johnson & Johnson’s (JNJ) Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International stating that Janssen does not intend to...
(BVF) Biovail Agreed to Develop Parkinson’s Drug
Biovail Corp. (BVF) today agreed to buy US and Canadian rights to develop and market JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson’s Disease (DPD) from Santhera Pharmaceuticals.
According to the deal, Biovail will...
(HSP) Hospira – FDA reinstated approval for Hospira’s generic version of Eloxatin
The US Food and Drug Administration (FDA) reinstated the previously suspended approval for Hospira’s (HSP) generic version of Eloxatin (chemotherapy agent), giving the company some relief for the time being. The Eloxatin issue has been in the news for the...
(HSP) Major Setback for Hospira Incorporated
In a major setback for Hospira Inc., (HSP) the company had to stop the shipment of its generic version of chemotherapy drug Eloxatin (oxaliplatin), within a few days of receiving regulatory approval. Apart from Hospira, Teva Pharmaceuticals...
(NOVN) Noven Pharmaceuticals Inc. – Aggressive Growth – Zacks Rank Buy
Noven Pharmaceuticals, Inc. (NOVN) is coming off of a great quarterly report in which revenues were up 29% and resulted in another earnings surprise.
Company Description
Noven develops and manufactures “transdermal”...
(MTXX) Matrixx Initiatives Inc. – Aggressive Growth – Zacks Rank Buy
Matrixx Initiatives, Inc. (MTXX) blew away analyst estimates, driven by strong organic sales growth for its fourth consecutive earnings surprise.
Company Description
Matrixx Initiatives, Inc. is a nutrient and drug...
(NOVN) Noven Pharmaceuticals, Inc. – Aggressive Growth – Zacks Rank Buy
Noven Pharmaceuticals, Inc. (NOVN) is growing steadily and shares are responding favorably to the latest earnings release.
Company Description
Noven Pharmaceuticals develops and manufactures transdermal...
(PETS) PetMed Express, Inc. – Momentum – Zacks Rank Buy
PetMed Express, Inc. (PETS), which sells prescription and non-prescription pet medications and health products for dogs, horses and cats, has seen its shares stage their own bear market rally in the past two weeks.
Sales Jumped 16% in Fiscal...
(MTXX) Matrix Initiatives, Inc. – Value – Zacks Rank Buy
Matrix Initiatives Inc. (MTXX) is cashing in on over-the-counter cough and cold products as revenue rose 26% in the fiscal third quarter. The company has surprised on estimates 4 consecutive quarters by an average of 28.48%. MTXX has a PEG ratio of only 0.9.
Company...
(MTXX) Matrixx Initiatives – fourth time in the last four quarters that Matrixx has beat estimates
Matrixx Initiatives, Inc. (MTXX) posted impressive third-quarter results in late January, sending its share price above its 6-month high.
Third-Quarter Results
Matrixx Initiatives is fresh off the heels of solid third-quarter results, reported on Jan 26, that...
(NOVN) Noven Pharmaceuticals -Beat Wall Street Estimates by 60% in the Third Quarter
Noven Pharmaceuticals, Inc. (NOVN) surprised on estimates by 60% in the third quarter as revenue rose 18%. The company has surprised on estimates 3 out of the last 4 quarters by an average of 36.67%. NOVN is trading at 14.5x forward earnings.
Company Description
Noven...
(PETS) PetMed Express – 25% higher than the consensus estimate
PetMed Express (PETS) estimates are rising as the company approaches its next earning announcement. Shares are trading just below the 52-week high and at fair valuations.
Company Description
PetMed Express is America’s largest pet pharmacy, delivering prescription...